Nemolizumab for lichen planopilaris

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, noncontrolled, prospective Phase 4 pilot testing nemolizumab in adults with LPP who report scalp pruritus (PP-NRS ≥4). Enrolled participants receive nemolizumab with symptom and safety assessments over the treatment period and may opt into an optional research scalp biopsy. Current biologics, JAK inhibitors, and DMARDs require an appropriate washout before enrollment to limit confounding effects. The single-center study at The Skin Center Dermatology Group emphasizes pruritus reduction and tolerability rather than randomized comparison.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years.
* Clinical and/or histopathologic diagnosis of LPP.
* Presence of scalp pruritus.
* Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1.
* Ability and willingness to provide written informed consent and comply with study procedures.
* Willingness to undergo optional scalp biopsy for research purposes.

Exclusion Criteria:

* Other forms of alopecia that may interfere with study assessments.
* Any systemic disease associated with hair loss.
* Inflammatory or infectious scalp disease that may interfere with the study.
* Any other conditions associated with pruritus.
* Prior use of nemolizumab.
* Current treatment with systemic or topical JAK inhibitors or biologics (unless appropriate washout period completed; minimum 12 weeks).
* Current treatment with DMARDs (unless appropriate washout period completed; minimum 12 weeks).
* Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or
* biologics.
* Current treatment with topical or intralesional corticosteroids (unless appropriate washout period completed; minimum 4 weeks).
* Any other current treatments for hair loss (e.g., oral/topical minoxidil, PRP) unless stable for at least 6 months or 3 months washout completed.
* Allergy or hypersensitivity to nemolizumab or any excipients.
* Pregnancy or unwillingness to use highly effective contraception.
* Any medical condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.

Where it's running

• The Skin Center Dermatology Group
  New City, New York, United States Recruiting

Study contacts

• Study coordinator: Peter Friedman, MD PhD
• Email: drfriedman@skincenterderm.com
• Phone: 8453520500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nemolizumab vs placebo in Chinese teens and adults with moderate-to-severe atopic dermatitis

  This study tests whether Nemolizumab can help moderate-to-severe atopic dermatitis in Chinese participants aged 12 and up, compared with a placebo.

  Recruiting Phase 3 Galderma R&D · Hangzhou, Zhejiang · NCT07762833

• Skin structure in atopic dermatitis patients treated with nemolizumab assessed by reflectance confocal microscopy

  This study tests whether nemolizumab changes skin structure in adults with moderate-to-severe atopic dermatitis using a noninvasive imaging method.

  Recruiting Hôpitaux Drôme Nord · Romans-sur-Isère, Drôme · NCT07730788

• Nemolizumab for infants with moderate-to-severe atopic dermatitis

  This study tests whether nemolizumab can be safely given to infants aged 6 to under 24 months to help manage moderate-to-severe eczema when topical treatments alone aren’t enough.

  Recruiting Phase 2 Galderma R&D · San Antonio, Texas · NCT07660835

• Nemolizumab for adults with systemic sclerosis

  This trial will test whether nemolizumab can reduce skin thickness in adults with systemic sclerosis over a 52-week treatment period.

  Recruiting at 3 sites Phase 2 Galderma R&D · Ann Arbor, Michigan and 2 other locations · NCT07047690

• Using nemolizumab (Nemluvio) to treat moderate-to-severe prurigo nodularis in adults

  This project tries nemolizumab (Nemluvio) in adults with moderate-to-severe prurigo nodularis to see if it reduces itching and symptoms by six months.

  Recruiting at 49 sites Galderma R&D · Birmingham, Alabama and 50 other locations · NCT06988618

• Nemolizumab for moderate-to-severe atopic dermatitis in adolescents and adults

  This will try nemolizumab in adolescents and adults with moderate-to-severe atopic dermatitis to see if it improves symptoms and patient-reported outcomes over six months.

  Recruiting at 81 sites Galderma R&D · Birmingham, Alabama and 107 other locations · NCT06988605

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.